Why Careium stock moves
Careium rose clearly, moving against a falling market.
Written after the close on ·
Why today
16,415 news analyzed todayCareium rose clearly, moving against a falling market.
No company news explains the move in the last session.
Over the last five trading days, Careium fell slightly while the market was roughly flat.
The rise likely reflects a sector bounce, since Industrials peers fell and the day's volume was about double normal.
Today's move of +2.17% was 2.0 times a normal day's 1.1%. OMX Stockholm 30 moved −1.01% on the same day.
Careium +2.17%OMX Stockholm 30 −1.01%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for Careium.
Careium earned more than expected in 5 out of 8 reports.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 6 out of 8 reports with a measured move, against about 63% of reports from Nordic companies.
Price targets
Latest price 28.20 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 0.63 SEK (February 11). For the current fiscal year, expected earnings per share changed from 2.06 SEK three months ago to 2.25 SEK now. 2026 estimate: 2.25 SEK. 2027 estimate: 2.79 SEK. One analyst made these estimates. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. September 21: Buy about 23 thousand SEK. September 11: Buy about 271 thousand SEK. July 30: Buy about 262 thousand SEK. January 9: Buy about 22 m SEK. January 9: Sell about 25 m SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 3 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −21% and earnings per share −45%.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 3 out of 3 years.Market cap (Now): 686 m SEKRevenue 2025: 854 m SEK
What the key figures say about Careium
The figures connect what Careium earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -0.47 SEK–2.40 SEK. Peers: Irisity -0.52 SEK, Nordic LEVEL Group -0.13 SEK, BIO-key International -$8.02. 2026 estimate: 2.25 SEK (2.25 SEK–2.25 SEK). 2027 estimate: 2.79 SEK (2.79 SEK–2.79 SEK).
What the company sold during the year.
2022–2025: 725 m SEK–871 m SEK. Peers: Irisity 89.7 m SEK, Nordic LEVEL Group 371 m SEK, BIO-key International $6.7M. 2026 estimate: 985 m SEK (985 m SEK–985 m SEK). 2027 estimate: 1.1 bn SEK (1.1 bn SEK–1.1 bn SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: −2.2%–9.7%. Peers: Irisity −182.4%, Nordic LEVEL Group −5.4%, BIO-key International −49.1%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −2.0%–8.6%. Peers: Irisity −50.2%, Nordic LEVEL Group −8.9%, BIO-key International −107.9%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 12.6–17.9. 2026 estimate: 12.5. 2027 estimate: 10.1.
What investors pay for each unit the company sells.
2022–2025: 0.30–0.85. Peers: Irisity 1.13, Nordic LEVEL Group 0.18, BIO-key International 0.72. 2026 estimate: 0.70. 2027 estimate: 0.64.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: 1.05–3.74.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 0.39–1.09. Peers: Irisity 0.44, Nordic LEVEL Group 0.49, BIO-key International 0.60.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 9.9–16.3.
Cash left after investments, divided by the number of shares.
2022–2025: -3.58 SEK–2.54 SEK. Peers: Irisity -0.06 SEK, Nordic LEVEL Group -0.07 SEK, BIO-key International -$2.05.
The percentage of assets financed by shareholders’ equity.
2022–2025: 57.1%–64.2%.
What to watch next, and why
The earnings report shows how Careium's revenue and profit have changed.
- Earnings report
The earnings report shows how Careium's revenue and profit have changed.
Add to calendar
More about Careium
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- David Granath, CFOBuyabout 23 thousand SEK
- David Granath, CFOBuyabout 271 thousand SEK
- Tove Christiansson, CEOBuyabout 262 thousand SEK
- Peter Lindell, board memberBuyabout 22 m SEK
- Kai Tavakka, board member (closely associated)Sellabout 25 m SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Careium usually moved about 11.1%. On a normal day it moves 1.1%.
+9.77% Why? +11.11% +0.85% −14.10%
10,000 SEK in Careium bought on December 10, 2021 is worth 8,790 SEK today, with dividends reinvested.
The same amount in OMX Stockholm 30 with dividends would have become 15,900 SEK.
What would 10,000 SEK in Careium be worth today? →
What would 10,000 SEK in Careium be worth today?
8,790 SEK
with dividends reinvested, bought on December 10, 2021. The same amount in OMX Stockholm 30 with dividends would have become 15,900 SEK.
At worst it was worth 2,400 SEK (November 15, 2022).
The five biggest days of the journey
· +48.9% · the whole market rose 0.1% the same day · report day
· +20.5% · the whole market rose 1.1% the same day · report day
· −17.4% · the whole market fell 1.5% the same day · report day
· +15.6% · the whole market rose 1.7% the same day · report day
· +15.5% · the whole market rose 2.2% the same day · report day
Earlier days
−2.08% market −0.11% Careium fell slightly over the past five trading days. Read →
Careium fell slightly over the past five trading days.
Careium has had no company news in the past two weeks.
Its last session saw a clear rise against a clearly falling OMX Stockholm 30, with trading running at about twice normal levels.
Earlier in October, Careium reported strong third-quarter growth, with net sales up about 22 percent, which is background rather than a cause of this week's move.
−1.08% market −0.32% Careium fell slightly without a company-news explanation. Read →
Careium fell slightly without a company-news explanation.
Over the last five trading days Careium fell clearly while OMX Stockholm 30 rose slightly, so it moved against the market.
The day's volume was well above its usual level, but the move was an ordinary size for Careium.
−0.71% market +0.83% Careium fell slightly, moving against a rising market. Read →
Careium fell slightly, moving against a rising market.
No company news explains the move.
Over the past five trading days Careium fell clearly, while OMX Stockholm 30 rose slightly.
The move was big for Careium, about twice a normal five-day stretch.
−3.10% market −0.08% Careium fell while the broader market was roughly flat. Read →
Careium fell while the broader market was roughly flat.
No company news explains that move.
Over the last five trading days Careium fell clearly, against a slightly rising OMX Stockholm 30, a big move for the stock.
Earlier news, a nomination committee set-up and a strong third-quarter report with rising sales, does not explain the recent drop.
Watch the next earnings report, due Thursday 11 February 2027.
−1.37% market −0.29% Careium fell, while the OMX Stockholm 30 slipped slightly. Read →
Careium fell, while the OMX Stockholm 30 slipped slightly.
No company news from that session explains the move.
Over the last five trading days, Careium was roughly unchanged while the market rose clearly, so it lagged.
The latest close sits well below the past year's high from early August.
−1.03% market +3.01% Careium was roughly flat over the week, moving less than the broader market, which rose clearly. Read →
Careium was roughly flat over the week, moving less than the broader market, which rose clearly.
Its latest session saw a clear drop, while OMX Stockholm 30 slipped only slightly, so Careium fell more than the market that day.
The week's company news came before the period, mainly its strong third-quarter report on 22 October, where sales and operating profit (EBIT, earnings before interest and tax) grew and beat expectations.
Trading was well below its usual level, which can make prices swing more on small orders.
−0.34% market +0.41% Careium held steady, moving less than the market. Read →
Careium held steady, moving less than the market.
Trading was about twice its usual level, but the move was an ordinary one for the stock.
Over the last five trading days it was roughly unchanged while OMX Stockholm 30 rose sharply.
No company news from the last session explains the move.
Earlier, Careium's third-quarter results beat expectations, with sales up 21.6 percent and operating profit up to SEK 26.7 million.
+2.06% market +1.57% Careium rose, moving in line with the market. Read →
Careium rose, moving in line with the market.
No company news explains that session's move.
Over the last five trading days, Careium rose very sharply while the OMX Stockholm 30 fell slightly.
That is a very big move for Careium, and it traded well above its usual volume.
Its latest quarterly report, published last week before the last session, showed sales up 21.6 percent and earnings beating expectations.
+10.23% market −3.67% Careium rose sharply over the last five trading days, moving against a market that fell sharply. Read →
Careium rose sharply over the last five trading days, moving against a market that fell sharply.
The rise was very big for the company, rare in the past year.
Its quarterly report, published yesterday, beat expectations: sales grew about 22 percent and operating profit (EBIT, earnings before interest and tax) rose strongly.
Analysts at ABG and SEB praised the results as a clean beat.
+9.77% market −2.51% Careium rose sharply on strong third-quarter results. Read →
Careium rose sharply on strong third-quarter results.
In the last session its shares rose very sharply while the OMX Stockholm 30 index fell sharply, so it moved against the market.
The likely reason is its third-quarter report, published that day, which beat expectations.
Net sales rose about 22 percent, and operating profit (EBIT, earnings before interest and tax) nearly doubled.
Learn more · Why do stocks go up and down?